Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0322 | Bendazac

Molecular Formula C16H14N2O3
Molecular Weight 282.29
Structure
Clearance The plasma clearance recorded for bendazac is given as 0.018 to 0.054 L/h/kg with a mean of 0.033 L/h/kg [A39863, A39869].
Volume of distribution The volume of distribution documented for bendazac is 0.16 L/kg [A39863, A39869].
Route of elimination About 60% of a dose of bendazac is eliminated via the urine as its primary metabolite, 5-hydroxybendazac [A39863, A39869]. Approximately 15% of a dose is eliminated as unchanged drug and bendazac glucuronide in the urine as well[A39863, A39869].
Protein binding Bendazac is >99% highly bound to plasma albumin protein in healthy subjects [A39863, A39869].
Half life The plasma elimination half-life recorded for bendazac is given as 1.7 to 5.2 hours, with a mean of 3.5 hours [A39863, A39869].
Absorption Administered as its lysine salt, a 500 mg oral tablet of bendazac is well absorbed into the human body with maximum plasma concentrations Cmax ranging from 35 to 55 mg/L being attained within 0.5 to 1 hour in healthy volunteers after oral administration of a single 500 mg dose [A39863, A39869].

S

M

S01BC07 Bendazac


[S01BC] Antiinflammatory agents, non-steroids


[S01B] ANTIINFLAMMATORY AGENTS


[S01] OPHTHALMOLOGICALS


[S] Sensory organs

M02AA11 Bendazac


[M02AA] Antiinflammatory preparations, non-steroids for topical use


[M02A] TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN


[M02] TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN


[M] Musculoskeletal system

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 2 companies from 1 notifications to the ECHA C&L Inventory.


H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P264, P270, P301+P312, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
rat LD50 intravenous 304mg/kg (304mg/kg) "Merck Index; an Encyclopedia of Chemicals, Drugs, and Biologicals", 11th ed., Rahway, NJ 07065, Merck & Co., Inc. 1989Vol. 11, Pg. 161, 1989.
mouse LD50 intraperitoneal 339mg/kg (339mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 884, 1979.
rat LD50 subcutaneous 714mg/kg (714mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 884, 1979.
mouse LD50 subcutaneous 406mg/kg (406mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 884, 1979.
rat LD50 oral 1200mg/kg (1200mg/kg) "Merck Index; an Encyclopedia of Chemicals, Drugs, and Biologicals", 11th ed., Rahway, NJ 07065, Merck & Co., Inc. 1989Vol. 11, Pg. 161, 1989.
mouse LD50 oral 1105mg/kg (1105mg/kg) "Merck Index; an Encyclopedia of Chemicals, Drugs, and Biologicals", 11th ed., Rahway, NJ 07065, Merck & Co., Inc. 1989Vol. 11, Pg. 161, 1989.
mouse LD50 intravenous 380mg/kg (380mg/kg) "Merck Index; an Encyclopedia of Chemicals, Drugs, and Biologicals", 11th ed., Rahway, NJ 07065, Merck & Co., Inc. 1989Vol. 11, Pg. 161, 1989.
rat LD50 intraperitoneal 319mg/kg (319mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 884, 1979.


  • ((1-(Phenylmethyl)-1H-indazol-3-yl)oxy)acetic acid ((1-Benzyl-1H-indazol-3-yl)oxy)acetic acid ((1-Benzyl-1H-indazol-3-yl)oxy)essigsaeure
    (1-Benzyl-1H-indazol-3-yloxy)-acetic acid 1-Benzyl-3-[1-(carboxy)methoxy]indazole 1-Benzylindazole-3-oxyacetic acid
    187B557 2-((1-Benzyl-1H-indazol-3-yl)oxy)acetic acid 2-(1-Benzyl-1H-indazol-3-yloxy)acetic Acid
    2-[1-(phenylmethyl)indazol-3-yl]oxyethanoic acid 2-[[1-(phenylmethyl)-3-indazolyl]oxy]acetic acid 20187-55-7
    5-23-11-00246 (Beilstein Handbook Reference) A814317 AB0011424
    AB07517 AC-6789 ACETIC ACID, ((1-BENZYL-1H-INDAZOL-3-YL)OXY)-
    ACETIC ACID, 2-[[1-(PHENYLMETHYL)-1H-INDAZOL-3-YL]OXY]- ACN-S004308 AF 1934 (Salt/Mix)
    AF 1934 [LYSINE] AF 983 AF-1934
    AKOS000279916 AX8043482 Acetic acid, ((1-(phenylmethyl)-1H-indazol-3-yl)oxy)-
    Acetic acid, [[1-(phenylmethyl)-1H-indazol-3-yl]oxy]- B4223 BCP15554
    BRN 0893958 BYFMCKSPFYVMOU-UHFFFAOYSA-N Bendaline (Salt/Mix)
    Bendazac (JAN/USAN/INN) Bendazac [USAN:BAN:INN:JAN] Bendazac [USAN:INN:BAN:JAN]
    Bendazac lysine (Salt/Mix) Bendazac, >=98% (HPLC) Bendazaco
    Bendazaco [INN-Spanish] Bendazacum Bendazacum [INN-Latin]
    Bendazolic acid Bindazac C-33090
    C16H14N2O3 CC-05268 CHEBI:31257
    CHEMBL1089221 CTK7J5556 D01594
    DTXSID1048334 Dogalina EINECS 243-569-2
    FT-0656910 G4AG71204O Iwazac
    Iwazac (TN) J-013103 KS-1230
    LS-11066 MFCD00866158 (97+%) OR350059
    Q862414 SC-79896 SCHEMBL25979
    SY014542 TC-306750 TRA0051400
    UNII-G4AG71204O Versus Z-4250
    ZINC1000 Zildasac [(1-BENZYL-1H-indazol-3-yl)-oxy]acetic acid
    [(1-Benzyl-1H-indazol-3-yl)oxy]acetic Acid [(1-Benzyl-3-indazolyl)oxy]acetic Acid [[1-(Phenylmethyl)-1H-indazol-3-yl]oxy]acetic acid
    bendazac

    DrugBank Name Bendazac
    DrugBank DB13501
    CAS Number 1082041-34-6, 1131622-55-3, 20187-55-7
    PubChem Compound 2313
    KEGG Drug D01594
    ChEBI 31257
    ChemSpider 2223
    Wikipedia Bendazac